Coherus BioSciences (CHRS) Reports Q2 Loss, Tops Revenue Estimates

Group 1 - Coherus BioSciences reported a quarterly loss of $0.14 per share, better than the Zacks Consensus Estimate of a loss of $0.21, and improved from a loss of $0.38 per share a year ago, representing an earnings surprise of 33.33% [1] - The company posted revenues of $64.98 million for the quarter ended June 2024, surpassing the Zacks Consensus Estimate by 13.85%, compared to year-ago revenues of $58.72 million [2] - Coherus BioSciences shares have declined approximately 62.8% since the beginning of the year, contrasting with the S&P 500's gain of 9% [3] Group 2 - The earnings outlook for Coherus BioSciences is mixed, with the current consensus EPS estimate for the coming quarter at -$0.08 on revenues of $59.86 million, and -$0.63 on revenues of $255.79 million for the current fiscal year [7] - The Zacks Industry Rank for Medical - Biomedical and Genetics is in the top 37% of over 250 Zacks industries, indicating that the industry outlook can significantly impact stock performance [8]